Novartis gives up on anti-CD40 antibody to treat Sjögren's due to 'benefit/risk profile'

cafead

Administrator
Staff member
  • cafead   Jan 31, 2025 at 11:32: AM
via Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome.

article source